Gobikrishnan, M (2013) Pre Clinical and Clinical Study on Pitha Pandu and the drug of choice is Karisalankanni Chooranam. Masters thesis, National Institute of Siddha, Chennai.
|
Text
320118313gobikrishnan.pdf Download (6MB) | Preview |
Abstract
The clinical study was to evaluate the Therapeutic efficacy of the siddha formulation “KARISALANKANNI CHOORANAM” which is indicated for pandu specifically in the ancient literature Sigicha Rathna Deepam (Ref: Page: 162). • Before the initiation of the study, Institutional Ethical Committee approval [Reg No: 1248/ac/oa/CPCSEA/4-02/2011] and Institutional Animal Ethical Committee approval [NIS/IEC/2011/03/02] was obtained by submitting well defined protocol, at NIS. • Institutional Ethical Committee and Institutional Animal Ethical Committee approval were obtained before the commencement of the trial by submitting the well defined protocol and proforma. • The raw drugs were collected from the reputed raw drug market in Chennai. • All the raw drugs were authenticated by Botanist in National Institute of Siddha. • The medicine was prepared by the Principal Investigator by following the standard operating procedure in Gunapadam laboratory, NIS. • Then the medicine was subjected to the preclinical studies, as per Who guidelines, in Pharmacology Lab, NIS and safety of the drug was ensured. • The prepared medicine was subjected to clinical trial at OPD and IPD of NIS. • Among the 60 patients screened in the OPD of Department of Maruthuvam, 40 patients who satisfied the inclusion and exclusion criteria were selected and all were females. Since the males did not satisfy the inclusion criteria and exclusion criteria were excluded from the study. • Clinical diagnosis of PithaPandu was made by Siddha and Modern methodology. • The trial drug “KARISALANKANNI CHOORANAM” - 1 gm is given continuously for 24 days. For OP patients ,they should visit the hospital once in 12 days. At each clinical visit clinical assessment is done and prognosis is noted. For IP patients the drug is provided daily and prognosis is noted. • Laborotary investigations are done at 0th day & 24th day of the trial. For IP patients, who is not in a situation to stay in the hospital for a long time is advised to attend the OPD for further continuation of the treatment. • Out of 40 patients, 30 were treated in OPD and 10 were treated in IPD. • Assessments and required Lab Investigations were carried out as per protocol and the concerned data was recorded in the proforma. • Followups of the patient for next 2 months in the OPD after the trial period were also carried out, without the trial drug. • The Statistical analysis showed the datas obtained from the Hematological parameters were statistically significant. CONCLUSION: To conclude Siddha way of approach is certainly the best treatment of Pitha pandu (Iron deficiency anaemia) in all aspects the trial drug Karisalankanni chooranam could avoid complications. • The raw drugs are readily available and easily preparable with least cost and more safety. • Toxicity study reveals safer study. • Clinical study revealed that the trail drug possess good improvement in 83.75% cases moderate improvement in 10.85%cases and 5.40% cases showed mild improvement. • The observed difference between the mean ± standard deviation of HB at before and after treatment were 9.34 ± .97 and 11.10 ± 2.24 which is statistically significant (p < 0.001).
| Item Type: | Thesis (Masters) |
|---|---|
| Uncontrolled Keywords: | Pitha Pandu ; Iron deficiency anaemia ; Karisalankanni Chooranam ; Pre Clinical and Clinical Study. |
| Subjects: | AYUSH > Maruthuvam |
| Depositing User: | Subramani R |
| Date Deposited: | 06 Jan 2019 16:40 |
| Last Modified: | 08 Jan 2019 02:28 |
| URI: | http://repository-tnmgrmu.ac.in/id/eprint/10344 |
Actions (login required)
 |
View Item |
